Brief: Mira Pharmaceuticals Ketamir-2 Shows Promising Safety Profile In Comparison To Traditional Ketamine In Preclinical Testing
24/06/2024 15:37
June 24 (Reuters) - Mira Pharmaceuticals Inc MIRA.O :
* MIRA PHARMACEUTICALS: KETAMIR-2 SHOWS PROMISING SAFETY
PROFILE
IN COMPARISON TO TRADITIONAL KETAMINE IN PRECLINICAL TESTING
Source text for Eikon: ID:nPnbDG2XPa
Further company coverage: MIRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mira Pharmaceuticals
See all newsBrief: Mira Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing
Brief: MIRA Pharmaceuticals Secures Worldwide Exclusive Rights To MIRA-55 And SKNY-1 - SEC Filing
Brief: Mira Pharmaceuticals Enters Into Amendment No 1 To Exclusive License Agreement With Miralogx
Brief: Mira Pharmaceuticals Inc - Completes Phase 1 Dosing Of Ketamir-2 - SEC Filing
Brief: Mira Pharmaceuticals Inc - Initiates Phase 1 Study Of Ketamir-2 - SEC Filing